Ozempic Cost in Delaware (2026): Prices, Insurance, and Savings Options

What Ozempic Costs at Delaware Pharmacies Right Now

The manufacturer list price set by Novo Nordisk for Ozempic (semaglutide injection) is $998 per month in 2026. Across Delaware retail pharmacies, the average cash-pay price mirrors that list price at roughly $998 for a one-month supply. That figure applies whether you fill at a CVS in Wilmington, a Walgreens in Dover, or an independent pharmacy in Newark.

Why Cash-Pay Prices Stay Near List Price

Unlike many generics, Ozempic has no FDA-approved generic equivalent. Novo Nordisk holds patent protection, and pharmacies have limited room to discount a sole-source branded biologic. GoodRx and similar coupon platforms may shave $50 to $150 off the cash price at certain Delaware locations, but the savings vary by zip code and by week.

How Dosing Affects Your Monthly Spend

Ozempic pens come in four dose strengths: 0.25 mg (initiation), 0.5 mg, 1.0 mg, and 2.0 mg. Standard titration starts at 0.25 mg weekly for four weeks, then 0.5 mg weekly for at least four weeks, before escalating to 1.0 mg or 2.0 mg based on glycemic response [1]. The monthly cost stays the same regardless of pen strength because Novo Nordisk prices each pen at one month of supply. A patient stabilized at 0.5 mg pays the same $998 as a patient on 2.0 mg when paying cash.

Comparison to National Averages

Delaware's average cash price tracks the national average closely. A 2024 IQVIA report estimated U.S. Mean net cost per GLP-1 prescription at $669 after rebates to payers, but that net price is invisible to uninsured patients at the pharmacy counter [2].

Delaware Medicaid Coverage for Ozempic

Delaware Medicaid does cover Ozempic, but only with prior authorization and only for its FDA-approved indication of type 2 diabetes. The state's preferred drug list, managed through the Diamond State Health Plan, requires prescribers to document a diagnosis of type 2 diabetes mellitus, prior trial of metformin (or a documented contraindication), and a current HbA1c value [3].

What the Prior Authorization Requires

The prescriber must submit clinical documentation showing that the patient has type 2 diabetes, has tried or cannot tolerate metformin, and has an HbA1c above a threshold set by the plan (typically 7.0% or higher). Approval is usually granted for 12 months and requires renewal with updated lab work.

Off-Label Weight Loss and Medicaid

Medicaid programs, including Delaware's, generally do not cover Ozempic for weight management alone. Semaglutide 2.4 mg (Wegovy) carries the FDA weight-management indication, but Delaware Medicaid's coverage of Wegovy is subject to separate formulary rules and is not guaranteed. Patients seeking GLP-1 therapy purely for obesity through Delaware Medicaid face significant coverage barriers.

Medicaid Managed Care Organizations in Delaware

Delaware contracts with managed care organizations (MCOs) including Highmark Health Options and AmeriHealth Caritas Delaware. Each MCO applies its own step-therapy and PA criteria. Patients should call the member services number on their Medicaid card to confirm Ozempic coverage before filling.

Insurance Coverage Across Delaware's Major Plans

Most major commercial insurers in Delaware, including Highmark Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare, include Ozempic on their formularies for type 2 diabetes. Coverage quality varies by plan tier.

Formulary Tier Placement Matters

Ozempic typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand/specialty) depending on the plan. Tier 3 placement usually means a copay of $40 to $75 per fill. Tier 4 can mean coinsurance of 25% to 40%, which on a $998 drug translates to $250 to $399 out of pocket before the Novo Nordisk savings card is applied.

Step Therapy and Prior Authorization

Many Delaware commercial plans require step therapy: the patient must try metformin first, sometimes a sulfonylurea or DPP-4 inhibitor second, before the plan approves a GLP-1 receptor agonist. In the SUSTAIN-7 trial (N=1,201), semaglutide 0.5 mg and 1.0 mg produced HbA1c reductions of 1.5% and 1.8%, respectively, outperforming dulaglutide 0.75 mg and 1.5 mg at both doses [4]. That head-to-head data can support a prescriber's appeal if a plan initially denies coverage.

Employer-Sponsored Plans

Large Delaware employers, including those in the banking and chemical sectors concentrated in northern New Castle County, often self-fund their health plans. Self-funded plans may have different formulary rules than fully insured plans from the same carrier. The benefits administrator or plan document (Summary Plan Description) is the definitive source for coverage details.

The Novo Nordisk Savings Card: How It Works in Delaware

Novo Nordisk offers the Ozempic Savings Card, which can reduce out-of-pocket costs to as little as $25 per 30-day supply for patients with commercial insurance [5]. The card covers up to $150 per fill on some offers, though terms change periodically.

Eligibility Rules

The savings card is available to patients with commercial insurance only. It excludes patients covered by Medicare, Medicaid, Tricare, or any other federal or state government-funded healthcare program. Delaware residents on those programs cannot use the card. Patients without insurance are also ineligible for the standard savings card, though Novo Nordisk runs a separate Patient Assistance Program (PAP) for uninsured patients below specific income thresholds.

How to Activate

Patients can enroll online through the Novo Nordisk website or receive a card through their prescriber's office. The card functions like a secondary insurance at the pharmacy. The pharmacist runs the primary insurance first, then applies the savings card to the remaining copay or coinsurance.

Annual Caps

The savings card carries an annual maximum benefit. Once that cap is reached, the patient reverts to their plan's standard cost-sharing for the rest of the calendar year. Patients on higher doses who fill monthly will hit the cap faster than those filling every 28 days on a lower dose.

Compounded Semaglutide in Delaware: Legality, Price, and Risks

Compounded semaglutide is available in Delaware through licensed 503A compounding pharmacies at approximately $199 per month, a fraction of branded Ozempic's price. This option exists because the FDA has intermittently listed semaglutide on its drug shortage list, which permits 503A pharmacies to compound copies of the drug.

The Legal Framework

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed compounding pharmacy may compound a copy of an FDA-approved drug when that drug appears on the FDA shortage list and the pharmacy holds a valid prescription for an individual patient [6]. Delaware's Board of Pharmacy licenses compounding pharmacies in the state and conducts inspections. The compound is not FDA-approved, meaning it has not undergone the same manufacturing controls, bioequivalence testing, or stability studies as branded Ozempic.

Price Advantages and Tradeoffs

At $199 per month versus $998, compounded semaglutide costs roughly 80% less. But patients should weigh several tradeoffs. Compounded products lack FDA manufacturing oversight. Potency can vary between batches. Sterility failures in compounding pharmacies have caused serious adverse events nationally, including a 2023 FDA warning letter to a Texas compounder for endotoxin contamination in injectable products [7].

What Happens When the Shortage Ends

If the FDA removes semaglutide from the shortage list, 503A pharmacies lose the legal basis to compound it. Patients using compounded semaglutide should have a plan for transitioning to branded Ozempic or Wegovy, including insurance pre-authorization, if compounding access is revoked. The FDA has signaled that it evaluates shortage status on a rolling basis.

Telehealth Access to Ozempic in Delaware

Delaware permits telehealth prescribing of Ozempic. A licensed prescriber can evaluate a patient via synchronous video visit, order labs, and transmit a prescription to any Delaware pharmacy. The Delaware Board of Medical Licensure and Discipline requires that telehealth prescribers hold a Delaware medical license or an applicable interstate compact license.

How Telehealth Visits Work for GLP-1 Prescriptions

A typical telehealth GLP-1 visit involves a medical history review, discussion of current medications, and review of recent lab work (fasting glucose, HbA1c, renal function panel). If labs are not recent, the prescriber orders them at a local lab draw site. Once results confirm eligibility, the prescriber writes the Ozempic prescription.

Telehealth-Specific Cost Considerations

Some telehealth platforms charge a monthly membership fee ($30 to $99) on top of the medication cost. Others bill the visit as a standard office visit to insurance. Patients should ask whether the platform's prescribers will handle prior authorization paperwork, because PA denials are the most common reason Delaware patients fail to fill an Ozempic prescription.

Strategies to Lower Your Ozempic Cost in Delaware

Several approaches can reduce what you actually pay.

Stack Insurance and the Savings Card

The single most effective strategy for commercially insured patients: confirm Ozempic is on your formulary, get PA approved, then apply the Novo Nordisk savings card to the remaining copay. This combination can bring the monthly cost to $25 to $75 for many patients.

Ask About Samples

Prescribers receive Ozempic sample pens from Novo Nordisk representatives. A sample pen covers one month of treatment and costs the patient nothing. Asking for samples during the titration phase (when you are on the low 0.25 mg dose) preserves a full-price pen for later months at the therapeutic dose.

Consider Compounded Semaglutide Carefully

For uninsured patients facing the full $998, compounded semaglutide at $199 per month represents significant savings. Verify the pharmacy's 503A license through the Delaware Board of Pharmacy, ask for a certificate of analysis for the specific batch, and confirm the concentration matches your prescribed dose.

Patient Assistance Programs

Novo Nordisk's PAP provides free Ozempic to uninsured patients whose household income falls below 400% of the federal poverty level. The application requires income documentation and a prescriber signature. Approval covers 90 days of medication, renewable for up to one year.

Delaware-Specific Resources

The Delaware Division of Medicaid and Medical Assistance (DMMA) operates a helpline for questions about prescription drug coverage. Delaware 211 can connect residents to local programs that assist with medication costs, including pharmaceutical company PAPs and nonprofit prescription assistance foundations.

Clinical Context: What You Get for the Cost

Ozempic's price reflects its clinical performance. In SUSTAIN-7 (N=1,201), semaglutide 1.0 mg weekly reduced HbA1c by 1.8% from baseline at 40 weeks, compared to 1.4% with dulaglutide 1.5 mg [4]. Weight loss was also greater: semaglutide 1.0 mg produced a mean reduction of 6.5 kg versus 3.0 kg with dulaglutide 1.5 mg.

Cardiovascular Benefit

The SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 26% compared to placebo over a median 2.1-year follow-up (HR 0.74, 95% CI 0.58 to 0.95, P=0.016) [8]. For patients with type 2 diabetes and established cardiovascular disease, this benefit adds clinical value beyond glycemic control.

Renal Considerations

The FLOW trial (N=3,533) showed semaglutide 1.0 mg reduced the risk of clinically important kidney outcomes by 24% in patients with type 2 diabetes and chronic kidney disease (HR 0.76, 95% CI 0.66 to 0.88) [9]. Delaware has an estimated 90,000 adults living with CKD, according to the CDC's Chronic Kidney Disease Surveillance System, making this finding relevant to a substantial portion of the state's diabetes population [10].

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, stated in 2024: "GLP-1 receptor agonists have shifted from second-line add-ons to first-line considerations for patients with type 2 diabetes who have or are at high risk for cardiovascular or kidney disease" [11].

The Endocrine Society's 2023 clinical practice guideline on pharmacologic treatment of obesity recommends semaglutide as a first-line pharmacotherapy option for adults with BMI of 30 kg/m² or greater, or 27 kg/m² or greater with a weight-related complication [12].

Patients in Delaware weighing $998 per month against these outcomes should discuss the expected duration of therapy with their prescriber. Ozempic is not a short-term medication; discontinuation typically results in partial regain of both HbA1c and body weight within 12 months, as shown in the STEP-1 extension data [13].